About OncoCyte
OncoCyte is a publicly listed company based in Irvine (United States) founded in 2009. Non-invasive diagnostic test solutions for cancer treatment are developed. OncoCyte has raised $15.35 million across 11 funding rounds from investors including SG Americas Securities and Pura Vida. The company has 49 employees. OncoCyte has completed 2 acquisitions, including Chronix Biomedical and Insight Genetics. Its chief executive, as recorded, is Ron Andrews. OncoCyte offers products and services including DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Lung cancer. Its legal entity is ONCOCYTE CORP. Its competitors include Biodesix, Mirvie and Epic Sciences; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2009 and based in Irvine, United States, non-invasive diagnostic tests for cancer are developed by the company. Operations focus on analyzing blood and urine samples for biomarkers through gene expression patterns compared against a database of known cancers. Tests such as DetermaRx for non-squamous NSCLC and DetermaRx EGFR for early-stage NSCLC are offered, enabling identification of lung, breast, and bladder cancers in the biotechnology sector.
- Headquarters Irvine, United States
- Employees 49
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website oncocyte.com
- Social LinkedIn X Facebook
- Legal Name Insight Molecular Diagnostics Inc.
- Annual Revenue$4.05 M (USD)115.58as on Dec 31, 2025
- Net Profit-$50.22 M (USD)17.21as on Dec 31, 2025
- EBITDA-$28.38 M (USD)-30.89as on Dec 31, 2025
- Total Equity Funding$15.35M (USD)
in 11 rounds
- Latest Funding Round$21.74M (USD), Post-IPO
Feb 2025
- InvestorsSG Americas Securities
& 1 more
- Employee Count49
- Investments & AcquisitionsChronix Biomedical
& 1 more
Products & Services of OncoCyte
OncoCyte offers a comprehensive portfolio of products and services, including DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Test to identify immune checkpoint inhibitor responders.
Detects early cancer progression after treatment.
Monitors kidney transplant health via DNA detection.
Monitors liver transplant health through DNA analysis.
Kit for assessing transplant graft health accurately.
Funding Insights of OncoCyte
OncoCyte has successfully raised a total of $15.35M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.74 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.35M
- Total Rounds 11
- Last Round Post-IPO — $21.74M
- First Round $7M
(May 2015)
- Investors Count 2
Latest 10 of 11 funding rounds of OncoCyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $21.74M | Post-IPO | – | – | – |
| Oct 2024 | $10.2M | Post-IPO | – | – | – |
| Apr 2024 | $15.81M | Post-IPO | – | – | – |
| Jun 2021 | Post-IPO | – | – | ||
| Jan 2021 | Post-IPO | – | – | ||
| Feb 2020 | $5M | Post-IPO | – | – | – |
| Mar 2018 | $10M | Post-IPO | – | – | – |
| Feb 2017 | $2.03M | Post-IPO | – | – | – |
| Sep 2016 | $10.55M | Post-IPO | – | – | – |
| Sep 2015 | $8.35M | Series B | – | – | – |
2 investors in total: 2 institutional.
Investors in OncoCyte
OncoCyte has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include SG Americas Securities and Pura Vida.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sgamericas.com | ||||
Investment management services are provided focusing on healthcare innovation. | puravidainvestments.com | New York, United States |
Investor details for OncoCyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OncoCyte
29 people are tracked at OncoCyte (15 in leadership, 4 in board & advisors, 10 in team); the tracked headcount is 49.
| Name | Role | Group |
|---|---|---|
Ron Andrews | CEO & President | Leadership |
Josh Riggs | President & CEO | Leadership |
Ekkehard Schütz | Chief Science Officer | Leadership |
Wen Li | Director, System Integration | Leadership |
Peter Hong | VP, General Counsel | Leadership |
Ryan Andrews | Vice President, Commercial | Leadership |
Brock Schweitzer | Senior Director, Pharma R&D | Leadership |
Shanet Oliver | CLIA Lab Operations Director | Leadership |
Eric Davis | Sr. Director, IT & Facilities | Leadership |
James Liu, CPA | Vice President Of Accounting, Controller, Treasurer, & Principal Accounting Officer | Leadership |
Julie Hufham | Associate Director, Marketing | Leadership |
Julia Beck | Director, Research Development | Leadership |
Mary Grace Sullivan | Director, CLIA Lab Services, Clinical Lab Scientist III | Leadership |
Mike Krnjaich | Regional Director | Leadership |
Dan Bailey | Associate Director, Product Management - Oncology | Leadership |
Andrew J. Last | Director | Board & advisors |
Alfred D. Kingsley | Director | Board & advisors |
Andy Arno | Chairman | Board & advisors |
Louis E. Silverman | Director | Board & advisors |
Yuh-Min Chiang | SVP, R&D & Product Development | Team |
9 more people are available in the full profile.
Complete people profiles for OncoCyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of OncoCyte
OncoCyte is a publicly listed company on the NASDAQ with ticker symbol IMDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Dec 2015
- Listed onNYSEAMERICAN: OCX
- Listed entityInsight Molecular Diagnostics Inc.
- Exchange sectorHealth technology
- ISINUS68235C2061
- Share price$2.99 (-5.68% on the day) · 2026-10-13
- Market capitalisation$97.8M
- EPS (diluted, trailing year)$-1.49
- Volume (last session)312,971
Financials of OncoCyte
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $4.0M | -$50.2M | -$28.4M |
| 2024 | $1.9M | -$60.7M | -$21.7M |
| 2023 | $1.5M | -$27.8M | -$20.6M |
| 2022 | $958,000 | -$72.9M | -$23.6M |
| 2021 | $2.2M | -$64.1M | -$19.6M |
Detailed financial statements for OncoCyte
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoCyte
OncoCyte has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Chronix Biomedical and Insight Genetics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Non-invasive diagnostics for cancer detection are developed through blood-based tests. | chronixbiomedical.com | San Jose, United States | 1997 | Feb 2021 | •••• | |
Molecular diagnostics company that is working to enhance the diagnosis, monitoring and treatment of cancer. | insightgenetics.com | Nashville, United States | 2007 | Jan 2020 | $12M |
Complete acquisition details for OncoCyte
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OncoCyte
6 dated milestones of OncoCyte across 16 years, from founding to its latest funding, stage changes and deals.
- Founded OncoCyte is founded.
- Funding First funding round of $7.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Insight Genetics.
- Acquisition Acquires Chronix Biomedical.
- Funding Latest funding round, Post-IPO, of $21.7M.
Competitors of OncoCyte
OncoCyte has 3 listed competitors in our database, 3 of them funded. They include Biodesix, Mirvie and Epic Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biodesix.com | 2005 | Boulder, United States | $200.16M | 217 | Cancer detection diagnostics assays are developed and offered. | |
| mirvie.com | 2019 | San Francisco, United States | $113.7M | 35 | Non-invasive blood tests for prenatal fetal health predictions are offered. | |
| epicsciences.com | 2008 | San Diego, United States | $204.5M | 98 | Non-invasive tests for detecting circulating tumor cells are provided. |
Detailed competitors of OncoCyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OncoCyte
Websites that share an audience with OncoCyte (oncocyte.com).
Websites whose visitors overlap most with OncoCyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
rsct.ir | rsct.ir | 100% | #11,039,072 | – | |
| transplantation.ru | 100% | #8,567,699 | View details | ||
cancerfed.com | cancerfed.com | 96% | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as OncoCyte (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oncocyte
Complete news archive for OncoCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoCyte
OncoCyte was founded in 2009 and raised its 1st funding round 6 years after it was founded.
OncoCyte is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Ron Andrews is the CEO of OncoCyte, as recorded in our data.
OncoCyte is a funded company, having raised a total of $15.35M across 11 funding rounds to date. The company's 1st funding round was a Series B of $8.35M, raised on May 2015.
OncoCyte has 49 employees.
Annual revenue of OncoCyte is $4.05M as on Dec 31, 2025.
Founded in 2009 and based in Irvine, United States, non-invasive diagnostic tests for cancer are developed by the company. Operations focus on analyzing blood and urine samples for biomarkers through gene expression patterns compared against a database of known cancers. Tests such as DetermaRx for non-squamous NSCLC and DetermaRx EGFR for early-stage NSCLC are offered, enabling identification of lung, breast, and bladder cancers in the biotechnology sector.
OncoCyte's top competitors include Biodesix, Mirvie and Epic Sciences.
OncoCyte offers DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Yes, OncoCyte is publicly traded on NASDAQ under the ticker symbol IMDX.
OncoCyte has made 2 acquisitions, including Chronix Biomedical, and Insight Genetics.
OncoCyte has 2 investors. Key investors include SG Americas Securities, and Pura Vida.